Company: CMND
Filing Date: 2025-11-26
Form Type: 424B5
Source: 0001213900-25-115106
Chunk: 41

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: 424B5
Chunk 41
---
 were vested as of such date;                           |

| ● | 2,603                                                                                                                     
 Common Shares issuable upon the exercise of Restricted Share Units issued to consultants under consulting agreements; and |

| ● | the                                                                                                                                  
 sale of (i) 225,833 Common Shares and associated common warrants at a public offering price of $9.00 per Common Share and associated 
 common warrant and (ii) 24,166 pre-funded warrants and associated common warrants at a public offering price of $8.97 per pre-funded 
 warrant and associated common warrant, in our follow-on public offering in September 2023.                                           |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to the one-for-30 consolidation of our issued and outstanding Common Shares that was effected on November 28, 2023.

<div align='center'>USE OF PROCEEDS</div>

Except as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds of this offering working capital, general corporate purposes and possible future acquisitions. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these proceeds.

The intended application of proceeds from the sale of any particular offering of securities using this prospectus will be described in the accompanying prospectus supplement relating to such offering. The precise amount and timing of the application of these proceeds will depend on our funding requirements and the availability and costs of other funds.

<div align='center'>9

DESCRIPTION OF SHARE CAPITAL</div>

General

The following is a summary of the material terms of our share capital, as set forth in our articles of association, as the same will be effective at the time of the consummation of this offering, and certain related sections of the BCBCA. The following summary is subject to, and is qualified in its entirety by reference to, the provisions of our articles of association and the applicable provisions of the BCBCA.

On September 30, 2022, our shareholders approved a one-for-30 Reverse Split of our issued and outstanding Common Shares. In addition, on November 28, 2023, we effected a one-for-30 consolidation of our issued and outstanding Common Shares. Except where otherwise indicated, all share and per share data in this prospectus have been retroactively restated to reflect the Reverse Split.

Authorized Share Capital

As of December